The role of platelets in peripheral vascular disease

European Journal of Vascular and Endovascular Surgery

Volumn 25, Issue 1, 2003, Pages 6-15

  Cassar, K ^a   Bachoo, P ^a   Brittenden, J ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Angioplasty; Peripheral vascular diseases; Platelet activation; Platelet aggregation; Platelet aggregation inhibitors; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DEXTRAN 40; DIPYRIDAMOLE; PLACEBO; TICLOPIDINE;

ANGIOPLASTY; ATHEROSCLEROSIS; BLOOD VESSEL OCCLUSION; BYPASS SURGERY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; GRAFT OCCLUSION; HUMAN; INTERVENTIONAL RADIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL ISCHEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; RESTENOSIS; REVIEW; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; UNSTABLE ANGINA PECTORIS; VASCULAR PATENCY; VASCULAR SURGERY; ARTERIOSCLEROSIS; BLOOD; BLOOD CLOTTING; HEMOSTASIS; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOCYTE; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, BALLOON; ARTERIOSCLEROSIS; BLOOD COAGULATION; BLOOD PLATELETS; GRAFT OCCLUSION, VASCULAR; HEMOSTASIS; HUMANS; MUSCLE, SMOOTH, VASCULAR; PERIPHERAL VASCULAR DISEASES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 0037270534     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejvs.2002.1795     Document Type: Review

References (92)

1. ANTITHROMBOTIC TRIALISTS' GROUP. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. ANTIPLATELET TRIALISTS' COLLABORATION. Collaborative Overview of randomised trials of antiplatelet therapy - II: Maintenance of Vascular Graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159-168.
3. ROSS R, GLOMSET JA. Atherosclerosis and the arterial smooth muscle cell. Science 1973; 180: 1332-1339.
4. ROSS R, GLOMSET JA. The pathogenesis of atherosclerosis (Part I). NEJM 1976; 295: 369-375.
5. ROSS R, GLOMSET JA. The pathogenesis of atherosclerosis (Part II). NEJM 1976; 295: 420-425.
6. D'SOUZA D, WU KK, HELLUMS JD, PHILLIPS MD. Platelet activation and arterial thrombosis. Lancet 1994; 334: 991-995.
7. 1 integrin and GPVI. J Biol Chem 1999; 274: 11897-11903.
8. ZAFFRAN Y, MEYER SC, NEGRESCU E, REDDY KB, FOX JE. Signaling across the platelet adhesion receptor glycoprotein Ib-IX induces alpha IIb beta 3 activation both in platelets and a transfected Chinese hamster ovary cell system. J Biol Chem 2000; 275: 16779-16787.
9. SHATTIL SJ. Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in and sideways. Thromb Haemost 1999; 82: 318-325.
10. GAARDER A, JONSEN J, LALAND S, HELLEM A, OWREN PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-533.
11. GAARDER A, LALAND S. Hypothesis for the aggregation of platelets by nucleotides. Nature 1964; 292: 909-911.
12. CATTANEO M, GACHET C. ADP receptors and clinical bleeding disorders. Arterioscler Throm Basic Biol 1999; 19: 2281-2285.
13. JIN J, QUINTON TM, ZHANG J, RITTENHOUSE SE, KUNAPULI SP. Adenosine diphosphate induced thromboxane A2 generation in human platelets requires coordinated signaling through integrin alpha IIb beta 3 and ADP receptors. Blood 2002; 99: 193-198.
14. MCEVER RP, BECKSTEAD JH, MOORE KL, MARSHALL-CARISON L, BAINTON DF. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989; 84: 92-99.
15. LORANT DE, TOPHAM MK, WHATLEY RE et al. Inflammatory roles of P-selectin. J Clin Invest 1993; 92: 559-570.
16. MCEVER RP. Selectins: novel receptors that mediate leukocyte adhesion during inflammation. Thromb Haemost 1991; 65: 223-228.
17. PALABRICA T, LOBB R, FURIE BC et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-851.
18. FAGGIOTTO A, ROSS R, HARKER L. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis 1984; 4: 323-340.
19. FITZGERALD DJ. Vascular biology of thrombosis: the role of platelet-vessel wall adhesion. Neurology 2001; 57: S1-S4.
20. COUGHLIN SR. Thrombin signaling and protease-activated receptors. Nature 2000; 407: 258-264.
21. ROSS R. The pathogenesis of atherosclerosis: an update. NEJM 1986; 314: 488-499.
22. TENNANT M, MCGEACHIE JK, DILLEY RJ, PRENDERGAST FJ. Histogenesis of arterial intimal hyperplasia and atherosclerosis. Aust NZJ Surg 1990; 69: 79-85.
23. HELDIN CG, WASTERSON A, WESTERMARK B. Platelet-derived growth factor. Mol Cell Endocrinol 1985; 39: 169-187.
24. WILCOX JN, SMITH KM, SCHWARTZ SM, GORDON D. Platelet-derived growth factor mRNA detection in human artherosclerotic plaques by in situ hybridization. J Clin Invest 1988; 82: 1134-1143.
25. JAWIEN A, BOWEN-POPE DF, LINDNER V, SCHWARTZ SM, CLOWES AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Inv 1992; 89: 507-511.
26. GORDON D, SCHWARTZ SM, BENDITT EP, WILCOX JN. Growth factors and cell proliferation in human artherosclerosis. Transplanation Proc 1989; 21: 3692-3694.
27. STEMERMAN MB, ROSS R. Experimental arteriosclerosis. I. Fibrous plaque formation in primates, an electron microscope study. J Exp Med 1972; 136: 769-789.
28. DI MINNO G, DAVI G, MARGAGLIONE M et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria - evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993; 92: 1400-1406.
29. FRIEDMAN RJ, STEMERMAN MB, WENZ B et al. The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. Smooth muscle cell proliferation and re-endothelialization. J C Invest 1977; 60: 1191-1201.
30. BANGA JD, SIAMA JJ. Diabetes mellitus, vascular disease and thrombosis. Clin Haematol 1986; 15: 564-592.
31. RUDERMAN NB, HAUDENSCHILD C. Diabetes as an atherogenic factor. Proc Cardiovasc Dis 1984; 26: 373-412.
32. HENDRA T, BETTERIDGE DJ. Platelet function, platelet prostanoids and vascular prostacyclin in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 1989; 35: 197-212.
33. WINOCOUR PD. Platelet abnormalities in Diabetes Mellitus. Diabetes 1992; 41: 26-31.
34. GUILLAUSSEAU PJ, DUPUY E, BRYCKAERT MC et al. Platelet derived growth factor in type I diabetes mellitus. Eur J Clin Invest 1989; 19: 172-175.
35. PACKHAM MA, MUSTARD JF. Platelet aggregation: relevance to thrombotic tendencies. Adv Exp Med Biol 1978; 102: 51-72.
36. LEE M, PATON RC, PASSA P, CAEN JP. Fibrinogen binding and ADP-induced aggregation in platelets from diabetic subjects. Thromb Res 1981; 24: 143-150.
37. SAVAGE B, ALMUS-JACOBS F, RUGGERI ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-666.
38. DE MARCO L, GIROLAMI A, RUSSELL S, RUGGERI SM. Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation. J Clin Invest 1985; 75: 1198-1203.
39. FERNANDEZ-ORTIZ A, BADIMON JJ, FALK E et al. Characterisation of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-1569.
40. TOSCHI V, GALLO R, LETTINO M et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599.
41. WILCOX JN, SMITH KM, SCHWARTZ SM, GORDON D. Localisation of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
42. SCHOOP W, LEVY H. Prevention of peripheral arterial occlusive disease with antiaggregants. Thromb Haemost 1983; 50: 137.
43. NORDESTGAARD AG, MARCUS CS, WILSON SE. Effect of aspirin and dipyridamole on sequential graft platelet accumulation after implantation of small diameter PTFE prosthesis. Platelets 1990; 1: 37-41.
44. ELDRUP-JORGENSEN J, MACKEY WC, CONNOLLY RJ et al. Evaluation of arterial prosthese in a baboon ex vivo shunt: the effect of graft material and flow on platelet deposition. Am J Surg 1985; 150: 185-190.
45. HANSON SR, KOTZE HF, SAVAGE B, HARKER LA. Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons. Arteriosclerosis 1985; 5: 595-603.
46. ALLEN BT, MATHIAS CJ, SICARD GA, WELCH MJ, CLARK RE. Platelet deposition on vascular grafts. The accuracy of in vivo quantitation and the significance of in vivo platelet reactivity. Ann Surg 1986; 203: 318-328.
47. ELDRUP-JORGENSEN J, CONNOLLY RJ, MACKEY WC et al. Antiplatelet therapy and vascular grafts. Studies in a baboon ex vivo shunt. Arch Surg 1986; 121: 778-781.
48. RUMISEK JD, WADE CE, KAPLAN K et al. The influence of early surface thromboreactivity on long-term arterial graft patency. Surgery 1989; 105: 654-661.
49. GOLDMAN M, NORCOTT HC, HAWKER RJ, DROLC Z, MCCOLLUM CN. Platelet accumulation on mature Dacron grafts in man. Br J Surg 1982; 69: S38-S40.
50. GOLDMAN M, NORCOTT HC, HAWKER RJ, HAIL C, DROLE Z, MCCOLLUM CN. Femoropopliteal bypass grafts - an isotope technique allowing in vivo comparison of thrombogenicity. Br J Surg 1982; 69: 380-382.
51. BREWSTER DC, LASALLE AJ, ROBISON JG, STRAYHORN EC, DARLING RC. Factors affecting patency of femoropopliteal bypass grafts. Surg Gyn & Obst 1983; 157: 437-442.
52. RADOMSKI MW, PALMER RMJ, MONCADA S. Comparative pharmacology of endothelium-dependent relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181-187.
53. RADOMSKI MW, PALMER RMJ, MONCADA S. The anti-aggregatory properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-646.
54. RADOMSKI MW, PALMER RMJ, MONCADA S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057-1058.
55. GRYGLEWSKI RJ, BOTTING RM, VANE JR. Mediators produced by the endothelial cell. Hypertension 1988; 12: 530-548.
56. COX JL, CHIASSON DA, GOTLIEB AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991; 34: 45-68.
57. DILLEY RJ, MCGEACHIE JK, TENNANT M. Vein to artery grafts: a morphological and histochemical study of the histogenesis of intimal hyperplasia. Aust N Z J Surg 1992; 62: 297-303.
58. GOLDMAN M, SIMPSON D, HAWKER RJ, NORCOTT HC, MCCOLLUM CN. Aspirin and dipyridamole reduce platelet deposition on prosthetic femoro-popliteal grafts in man. Ann Surg 1983; 198: 713-716.
59. 111indium-platelet deposition predict patency in prosthetic arterial grafts? Br J Surg 1983; 70: 635-638.
60. DUTCH BYPASS ORAL ANTICOAGULANTS OR ASPIRIN (BOA) STUDY GROUP. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet 2000; 355: 346-351.
61. GREEN RM, ROEDERSHEIMER LR, DEWEESE JA. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery 1982; 92: 1016-1026.
62. SHEEHAN SJ, SALTER MCP, DONALDSON DR, RAJAH SM, KESTER RC. Five year follow up of long-term aspirin/dipyridamole in femoropopliteal Dacron bypass grafts. Br J Surg 1987; 74: 330.
63. BECQUEMIN JP. Effect of Ticlopidine on the longterm patency of saphenous-vein bypass grafts in the legs. NEJM 1997; 337: 1726-1731.
64. RUTHERFORD RB, JONES DN, BERGENTZ SE et al. The efficacy of dextran 40 in preventing early postoperative thrombosis following difficult lower extremity bypass. J Vasc Surg 1984; 1: 765-773.
65. SHOENFELD NA, ELDRUP-JORGENSEN J, CONNOLLY R et al. The effect of low molecular weight dextran on platelet deposition onto prosthetic materials. J Vasc Surg 1987; 5: 76-82.
66. BATLLE J, DEL RIO F, LOPEZ FERNANDEZ MF, MARTIN R, LOPEZ BORRASCA A. Effect of dextran on factor VIII/von Willebrand factor structure and function. Thromb Haemost 1985; 54: 697-699.
67. NAZZAL W, OWUNWANNE A, CHRISTENSON JT. Direct platelet effect of low molecular weight dextran in small caliber PTFE grafts. Eur J Vasc Surg 1991; 5: 169-172.
68. WHITTEMORE AD, CLOWES AW, COUCH NP, MANNICK JA. Secondary femoropopliteal reconstruction. Ann Surg 1981; 193: 35-42.
69. KAGAN SA, MYERS SI. Mediators of restenosis. Surg Cl N America 1998; 78: 481-500.
70. NAKAMURA H, OHTSUBA KI. Ultrastructural appearance of atherosclerosis in human and experimentally induced animal models. Electron Microsc Rev 1992; 5: 129.
71. BOSCH JL, HUNINK MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology 1997; 204: 87-96.
72. KARCH LA, MATTOS MA, HENRETTA JP, MCLAFFERTY RB, RAMSEY DE, HODGSON KJ. Clinical failure after percutaneous transluminal angioplasty of the superficial femoral and popliteal arteries. J Vasc Surg 2000; 31: 880-887.
73. HARKER LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 1987; 60: 20-28.
74. LOSORDO DW, ROSENFIELD K, PIECZEK A, BAKER K, HARDING M, ISNER JM. How does angioplasty work? Serial analysis of human iliac arteries using intravascular ultrasound. Circulation 1992; 86: 1845-1858.
75. LYON RT, ZARINS CK, LU C-T, YANG C-F, GLAGOV S. Vessel, plaque, and lumen morphology after transluminal balloon angioplasty: quantitative study in distended human arteries. Arteriosclerosis 1987; 7: 306-314.
76. WILENTZ JR, SANBORN TA, HAUDENSCHILD CC, VALERI CR, RYAN TJ, FAXON DP. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 1987; 75: 636-642.
77. POSKITT KR, HARWOOD A, SCOTT DJ et al. Failure of peripheral arterial balloon angioplasty: does platelet deposition play a role? Eur J Vasc Surg 1991; 5: 541-547.
78. MILLER DD, RIVERA FJ, GARCIA OJ, PALMAZ JC, BERGER HJ, WEISMAN HF. Imaging of vascular injury with 99m Tc-labelled monoclonal antiplatelet antibody S12. Preliminary experience in human percutaneous transluminal angioplasty. Circulation 1992; 85: 1354-1363.
79. ROSSI P, KUUKASJARVI P, SALENIUS JP et al. Percutaneous transluminal angioplasty increases thromboxane A2 production in claudicants. Prost Leuk & Ess Fatty Acids 1997; 56: 369-372.
80. NYAMEKYE I, COSTA D, RAPHAEL M, BISHOP CC. Thrombosis and restenosis after peripheral angioplasty: does acute 111-indium platelet accumulation predict angioplasty outcome? Eur J Vasc Endovasc Surg 1997; 13: 388-393.
81. GOLINO P, AMBROSIO G, RAGNI M et al. Inhibition of leucocyte and platelet adhesion reduces neointimal hyperplasia after arterial injury. Thromb Haemost 1997; 77: 783-788.
82. HEISS HW, JUST H, MIDDLETON D, DEICHSEL G. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology 1990; 41: 263-269.
83. HESS H, MULLER-FASSBENDER H, INGRISCH H, MIETASCHK A. Prevention of re-occlusion after recanalisation of occluded arteries by the catheter method. Deutsche Medizinische Wochenschrift 1978; 103: 1994-1997.
84. PARSSON H, NORGREN L, IVANCEV K, THORNE J, JONSSON BA. Thrombogenicity of metallic vascular stents in arteries and veins - an experimental study in pigs. Eur J Vasc Surg 1990; 4: 617-623.
85. TARNOK A, MAHNKE A, MULLER M, ZOTZ RJ. Rapid in vitro biocompatibility assay of endovascular stents by flow cytometry using platetet activation and platelet-leukocyte aggregation. Cytometry 1999; 38: 30-39.
86. BRECKWOLDT WL, BELKIN M, GOULD K, ALLEN M, CONNOLLY RJ, TERMIN P. Modification of the thrombogenicity of a self-expanding vascular stent. J Invest Surg 1991; 4: 269-278.
87. VERHEYE S, MARKOU CP, SALAME MY et al. Reduced thrombus formation by hyaluronic acid coating of endovascular devices. Arterioscler Thromb Vasc Biol 2000; 20: 1168-1172.
88. MUELLER MR, SALAT A, STANGL P et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-1007.
89. YUSUF S, ZHAO F, MEHTA SR, CHROLAVICIUS S, TOCNONI G, FOX KK, AND THE CLOPIDOGREL IN UNSTABLE ANGINA TO PREVENT RECURRENT EVENTS TRIAL INVESTIGATORS. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. NEJM 2001; 345: 494-502.
90. KOHLER TR, KAUFMAN JL, KACOYANIS GP et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery 1984; 96: 462-466.
91. DONALDSON DR, SALTER MC, KESTER RC et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vasc Surg 1985; 19: 224-230.
92. MCCOLLUM C, ALEXANDER C, KENCHINGTON G, FRANKS PJ, GREENHALGH RM. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg 1991; 13: 150-162.